BioWorld MedTech

May 14, 2015

Financings: Glaukos files IPO, could be first public company in MIGS space

The latest development in the minimally invasive glaucoma surgical (MIGS) space comes from Glaukos (Laguna Hills, California) as the company has reportedly filed for an initial public offering (IPO) to raise $86 million. Read More

HRS annual Meeting : EP; HRS in danger of losing seat at the AMA RUC table

PLAC build-up: Cardio diagnostics broadening

Take a moment to complete critical reader survey

ResMed Fails to Hold SERVE: ResMed stock down after SERVE-HF misses its primary endpoint

Agreements/contracts: Abbott, GE Healthcare to integrate electrogram data

World in Review: W.L. Gore registers Excluder endoprosthesis in Australia

Patent Watch: USPTO issues patent allowance for Rosetta Cancer Origin Test

Briefly Noted

Product briefs

People in Places

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 14, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...